Moderna, Inc. $MRNA Stock Sold by Yousif Capital Management LLC

Yousif Capital Management LLC trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 7.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 37,814 shares of the company’s stock after selling 3,054 shares during the period. Yousif Capital Management LLC’s holdings in Moderna were worth $7,282,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Credit Capital Investments LLC bought a new position in shares of Moderna during the third quarter valued at $963,000. Compass Wealth Management LLC purchased a new stake in shares of Moderna during the third quarter valued at $385,000. Brookstone Capital Management purchased a new stake in shares of Moderna during the third quarter valued at $267,000. Root Financial Partners LLC bought a new stake in Moderna in the 3rd quarter worth about $232,000. Finally, SBI Securities Co. Ltd. increased its holdings in Moderna by 44.2% in the 3rd quarter. SBI Securities Co. Ltd. now owns 23,692 shares of the company’s stock worth $4,562,000 after buying an additional 7,267 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported positive Phase 3 INTerpath-001 results for the personalized mRNA cancer vaccine, intismeran autogene, used with Keytruda. The treatment reduced the risk of melanoma recurrence or death by 42%, while also improving distant metastasis-free survival. Oncologists described the findings as a major advance in melanoma care. Nature article
• Positive Sentiment: The results strengthen the case for Moderna’s oncology pipeline and could support a major future revenue stream beyond COVID-19 vaccines, particularly if additional trials demonstrate benefits in other cancers. Moderna has also advanced its mRNA bird-flu vaccine into a late-stage trial, adding another potential pipeline catalyst. Bird flu vaccine trial article
• Neutral Sentiment: Moderna’s recent addition to the Nasdaq-100 and analyst support provide structural and sentiment benefits, but these factors have less immediate influence than the cancer-vaccine readout. The stock had already posted an exceptionally strong rally, leaving the valuation highly sensitive to new clinical information. Nasdaq-100 inclusion article
• Negative Sentiment: Partial trial data appeared on social media ahead of Moderna and Merck’s planned ESMO presentation, triggering extreme volatility and a sharp selloff. The premature release disrupted the expected news event and encouraged a “sell-the-news” reaction. CNBC data leak article
• Negative Sentiment: Although clinically meaningful, the 42% reduction fell short of the market’s very high expectations after Moderna’s dramatic run-up. Investors also questioned whether the results will translate beyond melanoma, how quickly the product could reach the market, and its eventual commercial opportunity. The breach of near-term technical support and heightened trading swings add further pressure. Zacks analysis

Moderna Price Performance

NASDAQ MRNA opened at $200.10 on Friday. The business’s fifty day moving average price is $172.79 and its 200-day moving average price is $96.96. The stock has a market capitalization of $79.89 billion, a price-to-earnings ratio of -25.04 and a beta of 1.09. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $254.48.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same quarter in the previous year, the company posted ($2.13) earnings per share. Moderna’s revenue was up 2.1% compared to the same quarter last year. On average, equities analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Morgan Stanley boosted their target price on Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Piper Sandler raised their price target on shares of Moderna from $77.00 to $167.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Citigroup reaffirmed a “sell” rating on shares of Moderna in a report on Friday. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Moderna in a research note on Friday, August 28th. They issued a “hold” rating and a $125.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a report on Friday, August 21st. Seven analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $103.95.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the sale, the president directly owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. The trade was a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is owned by company insiders.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.